Radiation Dose During Percutaneous Treatment of Structural Heart Disease

Background With the increased application of structural heart intervention techniques, there is concern over increasing radiation dose, especially during lengthy procedures. Methods We compared data from 91 consecutive single-vessel percutaneous coronary interventions, 69 patent foramen ovale closur...

Full description

Saved in:
Bibliographic Details
Published in:Heart, lung & circulation lung & circulation, 2014-11, Vol.23 (11), p.1075-1083
Main Authors: Boland, John E., MSc, Wang, Louis W., MBBS, MM, Love, Bernard J., MHSc, Wynne, Dylan G., MBBS, PhD, FRACP, Muller, David W.M., MBBS, MD, FRACP, FACC
Format: Article
Language:English
Subjects:
Aged
Balloon Valvuloplasty
Cardiovascular
Coronary Angiography
Heart Diseases - diagnostic imaging
Heart Diseases - surgery
History, Ancient
Humans
Male
Middle Aged
Percutaneous Coronary Intervention
Percutaneous left atrial appendage occlusion
Percutaneous mitral valve intervention
Radiation
Radiation Dosage
Structural heart intervention
Time Factors
Transcatheter aortic valve
Transcatheter Aortic Valve Replacement
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background With the increased application of structural heart intervention techniques, there is concern over increasing radiation dose, especially during lengthy procedures. Methods We compared data from 91 consecutive single-vessel percutaneous coronary interventions, 69 patent foramen ovale closures, 25 atrial septal defect closures, 49 percutaneous transluminal mitral valvuloplasties, 57 balloon aortic valvuloplasties, 53 trans-catheter aortic valve implantations (TAVI), 21 left atrial appendage occlusions and 7 MitraClip® procedures. Results The following fluoroscopy times and dose-area product (median, interquartile range) were recorded: patent foramen ovale closure (7.8, 5.3-10.9 minutes; 16.9, 7.5-30.6 Gycm2 ), atrial septal defect closure (10.1, 7.3-13 minutes; 15.5, 11.6-30.5 Gycm2 ), percutaneous transluminal mitral valvuloplasty (14.3, 11.4-24.2 minutes; 37.4, 19.8-87.0 Gycm2 ), balloon aortic valvuloplasty (8.4, 5.2-13.2 minutes; 19.8, 10.2-30.0 Gycm2 ), Edwards Sapien™ TAVI (24.0, 19.3-34.4 minutes; 86.4, 64.0-111.4 Gycm2 ), Medtronic CoreValve® TAVI (19.4, 15.0-26.0 minutes; 101.9, 52.6-143.2 Gycm2 ), left atrial appendage occlusion (18.5, 15.7-29.1 minutes; 84.1, 36.4-140.0 Gycm2 ), Mitraclip® procedures (37.2, 14.2-59.9 minutes; 89.1, 26.2-118.7 Gycm2 ), coronary angiography and single vessel percutaneous coronary intervention (6.6, 5.1-11.0 minutes; 62.5, 37.0-95.8 Gycm2 ). Conclusion For structural heart interventions, dose-area product was not significantly greater than for coronary angiography with single-vessel percutaneous coronary artery intervention. This should be reassuring to patients and staff attending prolonged structural heart interventions.
ISSN:1443-9506
1444-2892
DOI:10.1016/j.hlc.2014.04.258